Reversing Neural Decay
First-in-class oral therapeutics for neurodegeneration
200M+
Addressable Patients
10+
Years of R&D
20+
Models or 5+ Species
The Global Burden
SBC003 starts here
Current Indications
Where SBC003 Starts
Three retinal indications today, with CNS neurodegeneration in discovery, all addressed by a single oral mechanism.
2M+ patients worldwide
Retinitis Pigmentosa
Inherited retinal dystrophy causing progressive vision loss from childhood, leading to legal blindness. No approved disease-modifying treatment exists.
Read more →200M+ affected globally
Dry AMD
The leading cause of irreversible vision loss in people over 50. Accounts for 85-90% of all AMD cases with no effective treatment available.
Read more →2M+ across major markets
Optic Atrophy
Progressive optic nerve degeneration affecting retinal ganglion cells. Commonly secondary to glaucoma and diabetic retinopathy.
Read more →Discovery · Next
CNS Neurodegeneration
Alzheimer's, Parkinson's, ALS, Stroke. Same neuroglobin mechanism, same single oral pill. Preclinical discovery underway.
Same molecule, expanding indicationsSBC003: One-Stop Solution for Neurons
An orally delivered compound that harnesses the neuroglobin pathway to halt and reverse neuronal loss; no injections required.
Neuro-Rescuing
Rescues neurons already committed to programmed cell death, effective even 3–6 hours after toxic insult and as late as 21 days postnatal in the rd10 model. Validated across multiple preclinical neuronal and animal models, with efficacy demonstrated in human iPSC-derived neurons, a critical translational signal.
Neuroprotective
The only compound with published evidence protecting neurons against all five major neurotoxic proteins: amyloid-β (Alzheimer's), α-synuclein (Parkinson's), tau, prion protein, and amylin.
Neurotrophic
Drives neurite outgrowth to restore neuronal connectivity. Higher efficacy demonstrated in human iPSC-derived neurons than in mouse neurons, a critical translational signal.
Oral. No injections.
SBC003 is a daily oral pill. It crosses the blood-brain and blood-retinal barriers with no structural moieties of toxic concern.
The Paradigm Is Broken. The Playbook Exists.
“Successful platform biotechs prove a novel mechanism with a pilot, then expand. Retina-first execution is precisely that playbook: a focused orphan indication validates the mechanism in humans, then the platform extends. SunRegen's retina-first strategy follows the proven platform playbook.”
The platform expansion thesis
RP → dry AMD → CNS neurodegeneration
SBC003 vs current standard of care
A Combined Addressable Market Across Multiple Indications
Across SBC003's lead indications: retinal degeneration first, CNS neurodegeneration next.
Invest in Neuro-Rescue
SunRegen is advancing toward Series A. We invite rigorous inquiry from institutional investors and strategic partners.
For Investors
Series A Financing
Targeting $35M+ to fund Phase I/II clinical trials in Retinitis Pigmentosa.
- Orphan drug pathway to RP approval, then Dry AMD expansion
- Mutation-agnostic; addresses 100% of RP patients vs. <1% with gene therapies
- Validated across 20+ models or 5+ species, including yeast, rodent, and primate models
For Partners
Scientific Collaboration
We welcome partnerships in research and clinical development across our portfolio of targeted therapeutics.
- Platform licensing for our compounds across retinal and CNS indications
- CRO/CMO and academic research partnerships